Pfizer Inc. Files 8-K on Financials

Ticker: PFE · Form: 8-K · Filed: 2025-02-04T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, financial-statements

Related Tickers: PFE

TL;DR

Pfizer dropped its 8-K on Feb 4th - check the financials!

AI Summary

On February 4, 2025, Pfizer Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and exhibits, with the company's principal executive offices located at 66 Hudson Boulevard East, New York, NY 10001-2192. Pfizer Inc. is incorporated in Delaware and operates within the Pharmaceutical Preparations industry.

Why It Matters

This filing provides investors with updated financial information and operational results for Pfizer Inc., crucial for assessing the company's current performance and future outlook.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Pfizer Inc.'s Results of Operations and Financial Condition, and to provide Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on February 4, 2025.

What is Pfizer Inc.'s principal executive office address?

Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York 10001-2192.

In which state is Pfizer Inc. incorporated?

Pfizer Inc. is incorporated in Delaware.

What is Pfizer Inc.'s Standard Industrial Classification (SIC) code?

Pfizer Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0000078003-25-000017.txt : 20250204 0000078003-25-000017.hdr.sgml : 20250204 20250204081120 ACCESSION NUMBER: 0000078003-25-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250204 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250204 DATE AS OF CHANGE: 20250204 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25585428 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20250204.htm 8-K pfe-20250204 0000078003 false 0000078003 2025-02-04 2025-02-04 0000078003 us-gaap:CommonStockMember 2025-02-04 2025-02-04 0000078003 pfe:NotesDue20271.000Member 2025-02-04 2025-02-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 4, 2025 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 2.02 Results of Operations and Financial Condition On February 4, 2025, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2024. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1

View on Read The Filing